Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $36.62 USD
Change Today 0.00 / 0.00%
Volume 0.0
STDAF On Other Exchanges
Symbol
Exchange
Xetra
OTC US
OTC US
As of 8:10 PM 07/24/15 All times are local (Market data is delayed by at least 15 minutes).

stada arzneimittel ag (STDAF) Key Developments

STADA Group Presents at 2015 Russian Pharmaceutical Forum, May-20-2015 12:05 PM

STADA Group Presents at 2015 Russian Pharmaceutical Forum, May-20-2015 12:05 PM. Venue: Corinthia Hotel, Saint Petersburg, Russia. Speakers: Christoph Dengler, Vice President Legal.

Stada-Arzneimittel AG Reports Group Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015

Stada-Arzneimittel AG reported group earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported group sales of EUR 486.2 million against EUR 507.4 million a year ago. EBITDA was EUR 79.2 million against EUR 97.7 million a year ago. EBITDA, adjusted was EUR 92.6 million against EUR 114.7 million a year ago. Net income was EUR 21.2 million or EUR 0.35 per share against EUR 35.0 million or EUR 0.35 per share a year ago. Net income, adjusted was EUR 37.9 million or EUR 0.62 per share against EUR 52.6 million or EUR 0.87 per share a year ago. Operating profit decreased by 20% to EUR 50.4 million against EUR 63.1 million a year ago. For the year 2015, the board expected to be able to achieve slight overall growth in Group sales adjusted for currency and portfolio effects. The board expects a substantial decrease in adjusted EBITDA and adjusted net income. The board expects the ratio of net debt, excluding further acquisitions, to adjusted EBITDA to be at a level of nearly 3 in 2015.

Stada-Arzneimittel AG, Q1 2015 Earnings Call, May 07, 2015

Stada-Arzneimittel AG, Q1 2015 Earnings Call, May 07, 2015

Stada-Arzneimittel AG Presents at 2015 Russian Pharmaceutical Forum, May-19-2015 11:20 AM

Stada-Arzneimittel AG Presents at 2015 Russian Pharmaceutical Forum, May-19-2015 11:20 AM. Venue: Corinthia Hotel, Saint Petersburg, Russia. Speakers: Dmitry Efimov, Senior Vice-President for Russia, CIS and South-Eastern Europe.

Stada-Arzneimittel Mulls Acquisitions

Stada-Arzneimittel AG (DB:SAZ) is seeking for acquisitions. Helmut Kraft, Chief Executive Officer of Stada-Arzneimittel said in full year 2014 Stada Arzneimittel AG earnings call, “It continues to allow us to make smaller bolt-on acquisitions with a focus on branded products once again and platforms being set up in the growth markets. And as you've seen through the slides the platforms are already there in each country. We just have to continue to supply them. So a steady flow of smaller product acquisitions preferably in the self-pay market, products in profitable, rapidly-growing niches is what we're aiming for. And products to round off our portfolio, a range expansion and different product categories, and, what we're really focusing on, the potential for products to be internationalized, or at least within a European setting, within our European subsidies.”

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STDAF:US $36.62 USD 0.00

STDAF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 3,712 INR -36.75
Impax Laboratories Inc $48.42 USD -0.83
Merck KGaA €94.42 EUR +1.90
Medicines Co/The $30.95 USD -2.53
UCB SA €66.84 EUR -0.16
View Industry Companies
 

Industry Analysis

STDAF

Industry Average

Valuation STDAF Industry Range
Price/Earnings 42.4x
Price/Sales 1.0x
Price/Book 2.2x
Price/Cash Flow 43.2x
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STADA ARZNEIMITTEL AG, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.